ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,346.99
-0.11%
US Tech 100
18,488.00
-0.25%
Dow Jones
38,798.99
-0.22%
Brent Oil
79.395
0.00%
Bitcoin
69,731.18
0.61%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. Canada
  5. TSXV
  6. Psybio Therapeutics Corp (PSYB)

  7. Psybio Therapeutics Corp (PSYB) News

PSYB

Psybio Therapeutics (PSYB)

Psybio Therapeutics Corp
Date:
Sort by:
 Showing the most relevant articles for your search:TSXV:PSYB
DateTimeSourceHeadlineSymbolCompany
12/07/202312:25AMPR Newswire (Canada)TSX Venture Exchange Stock Maintenance BulletinsTSXV:PSYBPsybio Therapeutics Corp
12/06/20238:32AMPR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - PSYBTSXV:PSYBPsybio Therapeutics Corp
12/06/20238:30AMPR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - PSYBTSXV:PSYBPsybio Therapeutics Corp
11/27/20237:53AMPR Newswire (Canada)Suspension de la négociation par l'Organisme canadien de réglementation des investissements - PSYBTSXV:PSYBPsybio Therapeutics Corp
11/27/20237:51AMPR Newswire (Canada)Canadian Investment Regulatory Organization Trading Halt - PSYBTSXV:PSYBPsybio Therapeutics Corp
12/08/20228:01AMPR Newswire (Canada)PsyBio Therapeutics Takes Initial Step to Help Protect the Sonoran Desert Toad as it Files Three New Provisional Patent Applications, Including Intellectual Property Protection for the Biosynthetic Production of 5-MeO-DMTTSXV:PSYBPsybio Therapeutics Corp
12/06/20228:09AMPR Newswire (Canada)PsyBio Therapeutics Files Four U.S. Patent Cooperation Treaty (PCT) Patent Applications Further Expanding Its Patent PortfolioTSXV:PSYBPsybio Therapeutics Corp
12/01/20227:30AMPR Newswire (Canada)PsyBio Therapeutics Announces Non-Brokered Private Placement FinancingTSXV:PSYBPsybio Therapeutics Corp
11/29/20227:20AMPR Newswire (Canada)PsyBio Therapeutics Reports Third Quarter 2022 Financial ResultsTSXV:PSYBPsybio Therapeutics Corp
10/11/20227:30AMPR Newswire (Canada)PsyBio Therapeutics Reaches Agreement to Conduct Initial Psilocybin Clinical TrialTSXV:PSYBPsybio Therapeutics Corp
09/19/20227:30AMPR Newswire (Canada)PsyBio Therapeutics Latest U.S. PCT (Non-Provisional) Patent Application AcceptedTSXV:PSYBPsybio Therapeutics Corp
09/07/20227:30AMPR Newswire (Canada)PsyBio Therapeutics to Present at Upcoming Investor Events in September 2022TSXV:PSYBPsybio Therapeutics Corp
08/29/20227:30AMPR Newswire (Canada)PsyBio Therapeutics Reports Second Quarter 2022 Financial ResultsTSXV:PSYBPsybio Therapeutics Corp
08/11/20227:30AMPR Newswire (Canada)PsyBio Therapeutics Strengthens IP Portfolio through Filing of Data to Support Previously Submitted Provisional Biosynthetic Production Patent ApplicationTSXV:PSYBPsybio Therapeutics Corp
08/08/20227:30AMPR Newswire (Canada)PsyBio Therapeutics Announces Expansion of Patent Portfolio with Additional Global Patent ApplicationsTSXV:PSYBPsybio Therapeutics Corp
06/27/20225:05PMPR Newswire (Canada)PsyBio Therapeutics to Seek Approval of Proposed Share Consolidation at Annual and Special Meeting of ShareholdersTSXV:PSYBPsybio Therapeutics Corp
06/02/20227:30AMPR Newswire (Canada)PsyBio Therapeutics Initiates Commercial Biosynthetic Based Process Development for Psycho-Targeted and Psychoactive CompoundsTSXV:PSYBPsybio Therapeutics Corp
05/30/20227:25AMPR Newswire (Canada)PsyBio Therapeutics Reports First Quarter 2022 Financial Results and Provides Corporate Update on Intellectual Property and Clinical Development MilestonesTSXV:PSYBPsybio Therapeutics Corp
05/16/20227:30AMPR Newswire (Canada)PsyBio Therapeutics Develops Commercial Purification Process for Second Generation Psycho-Targeted CompoundTSXV:PSYBPsybio Therapeutics Corp
05/06/20227:30AMPR Newswire (Canada)PsyBio Therapeutics Initiates Blood-Brain Barrier Permeability Testing for Pipeline Compounds to Enhance Portfolio DevelopmentTSXV:PSYBPsybio Therapeutics Corp
04/27/20227:30AMPR Newswire (Canada)PsyBio Therapeutics Begins Filing Global Provisional Patent Conversion Applications to Further Strengthen Biosynthetic Patent PortfolioTSXV:PSYBPsybio Therapeutics Corp
04/19/20227:30AMPR Newswire (Canada)PsyBio Therapeutics to Participate in Upcoming Investor Conferences in April 2022TSXV:PSYBPsybio Therapeutics Corp
04/13/20227:30AMPR Newswire (Canada)PsyBio Therapeutics Initiates Clinical Trial Site Selection ProcessTSXV:PSYBPsybio Therapeutics Corp
03/23/20227:30AMPR Newswire (Canada)PsyBio Therapeutics to Participate in the 2022 Maxim Group Virtual Growth Conference on March 28-30, 2022TSXV:PSYBPsybio Therapeutics Corp
03/15/20227:30AMPR Newswire (Canada)PsyBio Therapeutics Announces Proposed Acquisition of Everest Pharma (Pty) Ltd., a Lesotho Company in Southern Africa, as Part of Its Ongoing Impact Investment StrategyTSXV:PSYBPsybio Therapeutics Corp
03/02/20227:24PMPR Newswire (Canada)PsyBio Therapeutics Reports Annual 2021 Financial ResultsTSXV:PSYBPsybio Therapeutics Corp
02/02/20228:34AMPR Newswire (Canada)PsyBio Therapeutics to Participate in Citi's Psychedelic Drug Video Call SeriesTSXV:PSYBPsybio Therapeutics Corp
01/10/20226:30AMPR Newswire (Canada)PsyBio Therapeutics to Present at the H.C. Wainwright Bioconnect ConferenceTSXV:PSYBPsybio Therapeutics Corp
12/07/20217:30AMPR Newswire (Canada)PsyBio Therapeutics Successfully Completes First Pre-IND Meeting with the United States Food and Drug AdministrationTSXV:PSYBPsybio Therapeutics Corp
12/02/20217:30AMPR Newswire (Canada)PsyBio Therapeutics Sponsors 16 Collaborative Research Abstract Presentations at Two Scientific ConferencesTSXV:PSYBPsybio Therapeutics Corp
 Showing the most relevant articles for your search:TSXV:PSYB

Your Recent History

USOTC
CYDY
CytoDyn (QB)
USOTC
BMXI
Brookmount Explorations (PK)
USOTC
WDLF
Decentral Life (PK)
USOTC
VDRM
ViaDerma (PK)
USOTC
PSRU
Valiant Eagle (PK)
COIN
BTCUSD
Bitcoin
USOTC
AXXA
Exxe (PK)
USOTC
FNMA
Fannie Mae (QB)
NASDAQ
AVXL
Anavex Life Sciences
USOTC
NWBO
Northwest Biotherapeutics (QB)
NYSE
AMC
AMC Entertainment
NASDAQ
COOP
Mr Cooper
USOTC
ELTP
Elite Pharmaceuticals (QB)
USOTC
SPZI
Spooz (PK)
USOTC
KBLB
Kraig Biocraft Laborator... (QB)
USOTC
KEGS
1812 Brewing (PK)
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved